David S. Moura
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications
Biomarkers of prognosis and pazopanib response in soft tissue sarcoma: An exploratory analysis.
Journal: Therapeutic advances in medical oncology
Published: March 17, 2026
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 05, 2026
IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.
Journal: Cancer communications (London, England)
Published: November 13, 2025
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures.
Journal: Annals of medicine
Published: October 13, 2025
Validation of a Seven-Gene Predictive SIGNature for the Efficacy of Immuno-Oncology PD-1 Inhibitors in Patients with Sarcoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 18, 2025
Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS).
Journal: Neoplasia (New York, N.Y.)
Published: June 26, 2025
Which sarcoma requires PD1/PDL1 inhibitors, and what should be the best scheme? Present status and next steps.
Journal: Current opinion in oncology
Published: May 27, 2025
Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS).
Journal: bioRxiv : the preprint server for biology
Published: April 08, 2025
Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma.
Journal: Molecular oncology
Published: February 28, 2025
Last Updated: 09/26/2026